Editorial: Tacrolimus vs. Anti-Tumour Necrosis Factor Agents for Moderately to Severely Active Ulcerative Colitis

Alimentary Pharmacology and Therapeutics - United Kingdom
doi 10.1111/apt.13575
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Wiley

Related search

Correction: Tofacitinib for the Treatment of Moderately to Severely Active Ulcerative Colitis: A Systematic Review, Network Meta-Analysis and Economic Evaluation

BMJ Open Gastroenterology
Gastroenterology
2020English

Evidence for Differential Acquired Drug Resistance to Anti-Tumour Necrosis Factor Agents in Rheumatoid Arthritis

Annals of the Rheumatic Diseases
ImmunologyMolecular BiologyBiochemistryRheumatologyAllergyGenetics
2006English

Editorial: Anti-Tumour Necrosis Factor Α Antibodies - Can Efficacy Be Regained?

Alimentary Pharmacology and Therapeutics
HepatologyPharmacologyGastroenterology
2017English

Editorial: Therapeutic De-Escalation of Anti-Tumour Necrosis Factor Therapy - Is Less Enough?

Alimentary Pharmacology and Therapeutics
HepatologyPharmacologyGastroenterology
2017English

Editorial: Anti-Tumour Necrosis Factor Α Antibodies - Can Efficacy Be Regained? Authors' Reply

Alimentary Pharmacology and Therapeutics
HepatologyPharmacologyGastroenterology
2017English

Anti-Tumour Necrosis Factor Therapy for Ankylosing Spondylitis: International Experience

Annals of the Rheumatic Diseases
ImmunologyMolecular BiologyBiochemistryRheumatologyAllergyGenetics
2002English

Chronic Ulcerative Colitis Complicated by Atypical Carcinoid Tumour.

Journal of Clinical Pathology
MedicineForensic MedicinePathology
1986English

Cost-Effectiveness of Combination Disease-Modifying Antirheumatics vs. Tumour Necrosis Factor Inhibitors in Active Rheumatoid Arthritis: TACIT Trial

Arthritis Care and Research
Rheumatology
2020English

Fecal Microbiota Transplantation Ameliorates Active Ulcerative Colitis

Experimental and Therapeutic Medicine
MedicineCancer ResearchImmunologyMicrobiology
2020English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy